Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo

Cancer Biology and Therapy

Volumn 9, Issue 11, 2010, Pages 875-884

  Deng, Lin ^a   Li, Gang ^a   Li, Ronghui ^a   Liu, Qinglin ^a   He, Qiaowei ^a   Zhang, Jian ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Fasudil; Glioblastoma; Invasion; Matrix metalloproteinase; Rho kinase

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; FASUDIL; GELATINASE A; RHO KINASE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CONTROLLED STUDY; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; TUMOR XENOGRAFT;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTEIN KINASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHO-ASSOCIATED KINASES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954412580     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.11.11634     Document Type: Article

References (28)

1. Ohgaki H. Epidemiology of brain tumors. Methods Mol Biol 2009; 472:323-42.
2. Giese A, Westphal M. Glioma invasion in the central nervous system. Neurosurgery 1996; 39:235-52. (Pubitemid 26251544)
3. Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. FEBS Lett 2008; 582:2093-101.
4. Raftopoulou M, Hall A. Cell migration: Rho GTPases lead the way. Dev Biol 2004; 265:23-32. (Pubitemid 38018819)
5. Sahai E, Marshall CJ. Rho-GTPases and cancer. Nat Rev Cancer 2002; 2:133-42.
6. Schmitz AA, Govek EE, Bottner B, Van Aelst L. Rho GTPases: signaling, migration and invasion. Exp Cell Res 2000; 261:11-2.
7. Nobes CD, Hall A. Rho GTPases control polarity, protrusion and adhesion during cell movement. J Cell Biol 1999; 144:1235-44.
8. Riento K, Ridley AJ. ROCKS: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003; 4:446-56. (Pubitemid 36648590)
9. Salhia B, Rutten F, Nakada M, Beaudry C, Berens M, Kwan A, et al. Inhibition of Rho-kinase affects astrocytoma morphology, motility and invasion through activation of Rac1. Cancer Res 2005; 65:8792-800.
10. Rattan R, Giri S, Singh AK, Singh I. Rho A negatively regulates cytokine-mediated inducible nitric oxide synthase expression in brain-derived transformed cell lines: negative regulation of IKKalpha. Free Radic Biol Med 2003; 35:1037-50.
11. Yan B, Chour HH, Peh BK, Lim C, Salto-Tellez M. RhoA protein expression correlates positively with degree of malignancy in astrocytomas. Neurosci Lett 2006; 407:124-6. (Pubitemid 44397232)
12. Zohrabian VM, Forzani B, Chau Z, Murali R, Jhanwar-Uniyal M. Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res 2009; 29:119-23.
13. Shibuya M, Suzuki Y, Sugita K, Saito I, Sasaki T, Takakura K, et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 1992; 76:571-7.
14. Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther 2002; 93:225-32.
15. Kishi T, Hirooka Y, Masumoto A, Ito K, Kimura Y, Inokuchi K, et al. Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation 2005; 111:2741-7.
16. Shimokawa H, Rashid M. Development of Rhokinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci 2007; 28:296-302. (Pubitemid 46818464)
17. Oellers P, Schrfier U, Senner V, Paulus W, Thanos S. ROCKs are expressed in brain tumors and are required for glioma-cell migration on myelinated axons. Glia 2009; 57:499-509.
18. Ying H, Biroc SL, Li WW, Alicke B, Xuan JA, Pagila R, et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther 2006; 5:2158-64.
19. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 1999; 5:221-5.
20. Manning TJ, Parker JC, Sontheimer H. Role of lysophosphatidic acid and rho in glioma cell motility. Cell Motil Cytoskeleton 2000; 45:185-99. (Pubitemid 30151738)
21. Worthylake RA, Lemoine S, Watson JM, Burridge K. RhoA is required for monocyte tail retraction during transendothelial migration. J Cell Biol 2001; 154:147-60.
22. Totsukawa G, Wu Y, Sasaki Y, Hartshorne DJ, Yamakita Y, Yamashiro S, et al. Distinct roles of MLCK and ROCK in the regulation of membrane protrusions and focal adhesion dynamics during cell migration of fibroblasts. J Cell Biol 2004; 164:427-39.
23. Xue F, Takahara T, Yata Y, Xia Q, Nonome K, Shinno E, et al. Blockade of Rho/Rho-associated coiled coilforming kinase signaling can prevent progression of hepatocellular carcinoma in matrix metalloproteinase-dependent manner. Hepatol Res 2008; 38:810-7.
24. Vishnubhotla R, Sun S, Huq J, Bulic M, Ramesh A, Guzman G, et al. ROCK-II mediates colon cancer invasion via regulation of MMP-2 and MMP-13 at the site of invadopodia as revealed by multiphoton imaging. Lab Invest 2007; 87:1149-58. (Pubitemid 47609026)
25. Li M, Li Z, Sun X. Statins suppress MMP2 secretion via inactivation of RhoA/ROCK pathway in pulmonary vascular smooth muscles cells. Eur J Pharmacol 2008; 591:219-23.
26. Yamaguchi S, Tanabe K, Takai S, Matsushima-Nishiwaki R, Adachi S, Iida H, et al. Involvement of Rho-kinase in tumor necrosis factor-alpha-induced interleukin-6 release from C6 glioma cells. Neurochem Int 2009; 55:438-45.
27. Ikegaki I, Hattori T, Yamaguchi T, Sasaki Y, Satoh SI, Asano T, et al. Involvement of Rho-kinase in vascular remodeling caused by long-term inhibition of nitric oxide synthesis in rats. Eur J Pharmacol 2001; 427:69-75.
28. Satoh S, Toshima Y, Hitomi A, Ikegaki I, Seto M, Asano T. Wide therapeutic time window for Rhokinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model. Brain Res 2008; 1193:102-8.